» Articles » PMID: 12611641

Reactive Oxygen Species, Antioxidant Mechanisms and Serum Cytokine Levels in Cancer Patients: Impact of an Antioxidant Treatment

Overview
Journal J Cell Mol Med
Date 2003 Mar 4
PMID 12611641
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: So far, it is not well established whether oxidative stress found in cancer patients results from an increased production of oxidants in the body or from a failure of physiological antioxidant systems. To further investigate this question we have assessed the blood levels of reactive oxygen species as a marker of free radicals producing oxidative stress and the most relevant of the physiological body enzymes counteracting reactive oxygen species, namely glutathione peroxidase and superoxide dismutase. Serum levels of proinflammatory cytokines and IL-2 were also investigated. All these parameters were studied in relation to the clinically most important index of disease progression, namely Performance Status (ECOG PS). We also tested the reducing ability of different antioxidant agents on reactive oxygen species levels by measuring the increase in glutathione peroxidase activity, and the reduction of serum levels of IL-6 and TNF.

Design, Setting And Subjects: We carried out an open non randomized study on 28 advanced stage cancer patients (stage III, 10.7%, and stage IV, 89.3%) with tumours at different (8) sites: all were hospitalized in the Medical Oncology Dept, University of Cagliari Interventions. The patients were divided into 5 groups and a different antioxidant treatment was administered to each group. The selected antioxidants were: alpha lipoic acid 200 mg/day orally, N-acetylcysteine 1800 mg/day i.v. or carboxycysteine-lysine salt 2.7 g/day orally, amifostine 375 mg/day i.v., reduced glutathione 600 mg/day i.v., vitamin A 30000 IU/day orally plus vitamin E 70 mg/day orally plus Vitamin C 500 mg/day orally. The antioxidant treatment was administered for 10 consecutive days.

Results: Our results show that all but one of the antioxidants tested were effective in reducing reactive oxygen species levels and 2 of them (cysteine-containing compounds and amifostine) had the additional effect of increasing glutathione peroxidase activity. Comprehensively, the "antioxidant treatment" was found to have an effect both on reactive oxygen species levels and glutathione peroxidase activity. The antioxidant treatment also reduced serum levels of IL-6 and TNF. Patients in both ECOG PS 0-1 and ECOG PS 2-3 responded to antioxidant treatment.

Citing Articles

Unveiling the Multifaceted Management of Oral Mucositis in Cancer Patients: A Narrative Review.

R S, Pandiyan I Cureus. 2024; 16(2):e55213.

PMID: 38558646 PMC: 10981506. DOI: 10.7759/cureus.55213.


Targeting the Metabolic Paradigms in Cancer and Diabetes.

Bosso M, Haddad D, Madhoun A, Al-Mulla F Biomedicines. 2024; 12(1).

PMID: 38255314 PMC: 10813379. DOI: 10.3390/biomedicines12010211.


Chemotherapy agents reduce protein synthesis and ribosomal capacity in myotubes independent of oxidative stress.

Guo B, Bennet D, Belcher D, Kim H, Nader G Am J Physiol Cell Physiol. 2021; 321(6):C1000-C1009.

PMID: 34705587 PMC: 8714989. DOI: 10.1152/ajpcell.00116.2021.


Spectrophotometric assays for evaluation of Reactive Oxygen Species (ROS) in serum: general concepts and applications in dogs and humans.

Rubio C, Ceron J BMC Vet Res. 2021; 17(1):226.

PMID: 34174882 PMC: 8235564. DOI: 10.1186/s12917-021-02924-8.


Alleviation of cisplatin-induced hepatotoxicity by gliclazide: Involvement of oxidative stress and caspase-3 activity.

Taghizadeh F, Hosseinimehr S, Zargari M, Karimpour Malekshah A, Mirzaei M, Talebpour Amiri F Pharmacol Res Perspect. 2021; 9(3):e00788.

PMID: 34003600 PMC: 8130655. DOI: 10.1002/prp2.788.


References
1.
Mantovani G, Maccio A, Melis G, Mura L, Massa E, Mudu M . Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha-lipoic acid and N-acetyl cysteine. Int J Cancer. 2000; 86(6):842-7. DOI: 10.1002/(sici)1097-0215(20000615)86:6<842::aid-ijc13>3.0.co;2-k. View

2.
Buonocore G, Perrone S, Longini M, Terzuoli L, Bracci R . Total hydroperoxide and advanced oxidation protein products in preterm hypoxic babies. Pediatr Res. 2000; 47(2):221-4. DOI: 10.1203/00006450-200002000-00012. View

3.
Mantovani G, Maccio A, Mura L, Massa E, Mudu M, Mulas C . Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med (Berl). 2001; 78(10):554-61. DOI: 10.1007/s001090000137. View

4.
Kong Q, Lillehei K . Antioxidant inhibitors for cancer therapy. Med Hypotheses. 1998; 51(5):405-9. DOI: 10.1016/s0306-9877(98)90036-6. View

5.
Navarro J, Obrador E, Carretero J, Petschen I, Avino J, Perez P . Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. Free Radic Biol Med. 1999; 26(3-4):410-8. DOI: 10.1016/s0891-5849(98)00213-5. View